Institut de Chimie des Milieux et Matériaux de Poitiers, UMR CNRS 7285, 4 rue Michel Brunet, TSA 51106, B28, 86073 Poitiers CEDEX 09, France.
CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.
Biomolecules. 2019 Feb 12;9(2):60. doi: 10.3390/biom9020060.
Fast clearance, metabolism, and systemic toxicity are major limits for the clinical use of anti-cancer drugs. Histone deacetylase inhibitors (HDACi) present these defects, despite displaying promising anti-tumor properties on tumor cells in vitro and in in vivo models of cancer. The specific delivery of anti-cancer drugs into the tumor should improve their clinical benefit by limiting systemic toxicity and by increasing the anti-tumor effect. This paper deals with the synthesis of the polymeric nanoparticle platform, which was produced by Ring-Opening Metathesis Polymerization (ROMP), able to release anti-cancer drugs in dispersion, such as histone deacetylase inhibitors, into mesothelioma tumors. The core-shell nanoparticles (NPs) have stealth properties due to their poly(ethylene oxide) shell and can be viewed as universal nano-carriers on which any alkyne-modified anti-cancer molecule can be grafted by click chemistry. A cleavage reaction of the chemical bond between NPs and drugs through the contact of NPs with a medium presenting an acidic pH, which is typically a cancer tumor environment or an acidic intracellular compartment, induces a controlled release of the bioactive molecule in its native form. In our in vivo syngeneic model of mesothelioma, a highly selective accumulation of the particles in the tumor was obtained. The release of the drugs led to an 80% reduction of tumor weight for the best compound without toxicity. Our work demonstrates that the use of theranostic nanovectors leads to an optimized delivery of epigenetic inhibitors in tumors, which improves their anti-tumor properties in vivo.
快速清除、代谢和全身毒性是抗癌药物临床应用的主要限制。组蛋白去乙酰化酶抑制剂 (HDACi) 尽管在体外和癌症动物模型中显示出有希望的抗肿瘤特性,但存在这些缺陷。将抗癌药物特异性递送至肿瘤中,可以通过限制全身毒性和增加抗肿瘤作用来提高其临床获益。本文涉及聚合纳米颗粒平台的合成,该平台通过开环复分解聚合 (ROMP) 产生,能够将分散的抗癌药物(如组蛋白去乙酰化酶抑制剂)释放到间皮瘤肿瘤中。核壳纳米颗粒 (NPs) 具有聚(氧化乙烯)壳的隐身特性,并且可以被视为通用的纳米载体,其上可以通过点击化学接枝任何炔基修饰的抗癌分子。通过 NPs 与呈现酸性 pH 的介质接触,即通常是癌症肿瘤环境或酸性细胞内隔室,使 NPs 与药物之间的化学键发生裂解反应,以控制形式释放生物活性分子。在我们的间皮瘤同基因体内模型中,获得了粒子在肿瘤中的高度选择性积累。药物的释放导致最佳化合物的肿瘤重量减少了 80%,而没有毒性。我们的工作表明,使用治疗性纳米载体可优化将表观遗传抑制剂递送至肿瘤中,从而提高其体内抗肿瘤特性。